Xianju Pharmaceutical Co., Ltd., A Subsidiary Of Fuan Pharmaceutical Group Co., Ltd., Has Received The Approval Notification For The Marketing Authorization Application Of Lipoic Acid And Palonosetron Hydrochloride As Chemical Active Pharmaceutical Ingredients (APIs).

Feb 13, 2026

Leave a message

Guang'an Kate Pharmaceutical Co., Ltd. (hereinafter referred to as "Guang'an Kate"), a wholly-owned subsidiary of Fuan Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "the Company"), recently received the Approval Notification for the Marketing Authorization Application of Chemical Active Pharmaceutical Ingredients issued by the National Medical Products Administration.The relevant details are announced as follows:

 

API Name Registration No. Manufacturer Packaging Specification Approval Conclusion
Lipoic Acid Y20210000898 Guang'an Kate 15kg/drum After review, this product complies with the relevant requirements for drug registration, and the production and registration application for this product is approved.
Palonosetron Hydrochloride Y20210000631 Guang'an Kate 500g/drum After review, this product complies with the relevant requirements for drug registration, and the production and registration application for this product is approved.

 

Lipoic acid is mainly used for the treatment of sensory abnormalities caused by diabetic peripheral neuropathy. Palonosetron hydrochloride is an antiemetic drug.

According to the information platform of the National Medical Products Administration (NMPA), up to the present date, a total of 14 enterprises have obtained approval for the marketing authorization application of lipoic acid as an active pharmaceutical ingredient (API), and 20 enterprises have obtained approval for palonosetron hydrochloride as an API.

The approval of the above-mentioned APIs will allow their use in domestic marketed preparations and further enrich the product portfolio of the subsidiary.

However, affected by factors such as the progress of GMP compliance inspections, national policies, and changes in the market environment, the production and sales schedule as well as the specific sales performance of the above-mentioned APIs are subject to uncertainty.

Investors are advised to make prudent decisions and pay attention to investment risks.

Send Inquiry
Contact usif have any question

You can either contact us via phone, email or online form below. Our specialist will contact you back shortly.

Contact now!